Why Are Brain Tumors More Deadly for Kids in Poorer Neighborhoods?
By Dennis Thompson HealthDay Reporter
MONDAY, June 24, 2024 -- U.S. children with inoperable brain tumors appear to die sooner and find it harder to get care if they live in poorer neighborhoods, a new study finds.
Children from higher-income areas had more than double the average survival time than kids from poorer neighborhoods -- 480 days versus 235 days, depending if a census tract had an average household income higher or lower than $50,000.
Kids in wealthier neighborhoods were also able to travel significantly longer distances to get the best medical care, 1,550 miles versus 1,114 miles for children in lower-income areas, researchers reported recently in the Journal of Neurosurgery.
“Children with these inoperable gliomas require access to specialized centers of care and clinical trials in the hopes of extending their lives, yet we are seeing that socioeconomic factors are linked to worsening survival,” said lead researcher Dr. John Lee, an incoming neurosurgery resident at University of Michigan Health.
“It’s critical that we understand the reasons for this disparity, so that we can ensure all patients have opportunities for life-prolonging care,” Lee added in a university news release.
The study tracked nearly 100 children being treated for two types of incurable brain tumors, diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), between 2000 and 2022.
Education levels also made a difference in a child’s treatment, researchers found.
Kids in higher-educated areas were able to travel an average 2,964 miles for cancer care, versus 478 miles for children in neighborhoods with the least education.
Families with fewer financial resources might be less capable of travel to specialized cancer centers where they can receive second opinions, different treatment options and enrollment in clinical trials, Lee said.
“Additionally, patients whose families have lower levels of education may have less knowledge about the signs and symptoms of a condition, early screening programs and treatment options,” said senior researcher Dr. Karin Muraszko, a professor of neurosurgery at University of Michigan Medical School.
“However, our research uncovered disparities in survival despite no significant differences in rates of clinical trial enrollment or time until initiation of treatment between patients from different census tracts,” Muraszko added. “Future studies should aim to understand the exact mechanism through which this gap is created.”
Sources
- University of Michigan, news release, June 20, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Organic Ground Beef Sold at Whole Foods May Be Contaminated With E. Coli, USDA Says
THURSDAY, June 5, 2025 — Some packages of organic ground beef sold at Whole Foods stores across the country may be contaminated with E. coli, federal officials have...
RFK Jr. Calls for a Review of Abortion Pill Mifepristone
THURSDAY, June 5, 2025 — U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has ordered a fresh safety review of mifepristone, a drug commonly used in medication...
More U.S. Teens Are Now Taking Wegovy for Weight Loss
THURSDAY, June 5, 2025 — More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment. But experts...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.